Peptide interactions with G-protein coupled receptors.

Peptide recognition by G-protein coupled receptors (GPCRs) is reviewed with an emphasis on the indirect approach used to determine the receptor-bound conformation of peptide ligands. This approach was developed in response to the lack of detailed structural information available for these receptors. Recent advances in the structural determination of rhodopsin (the GPCR of the visual system) by crystallography have provided a scaffold for homology modeling of the inactive state of a wide variety of GPCRs that interact with peptide messages. Additionally, the ability to mutate GPCRs and assay compounds of similar chemical structure to test a common binding site on the receptor provides a firm experimental basis for structure-activity studies. Recognition motifs, common in other well-studied systems such as proteolytic enzymes and major histocompatibility class receptors (MHC) are reviewed briefly to provide a basis of comparison. Finally, the development of true peptidomimetics is contrasted with nonpeptide ligands, discovered through combinatorial chemistry. In many systems, the evidence suggests that the peptide ligands bind at the interface between the transmembrane segments and the extracellular loops, while nonpeptide antagonists bind within the transmembrane segments. Plausible models of GPCRs and the mechanism by which they activate G-proteins on binding peptides are beginning to emerge.

[1]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[2]  F. Richards,et al.  Thermodynamics of protein-peptide interactions in the ribonuclease S system studied by titration calorimetry. , 1990, Biochemistry.

[3]  M. Ermolaeva,et al.  Receptor-G protein coupling is established by a potential conformational switch in the beta gamma complex. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Determination of peptide contact points in the human angiotensin II type I receptor (AT1) with photosensitive analogs of angiotensin II. , 1999, Molecular endocrinology.

[5]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[6]  A. Billich,et al.  Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions. , 1991, Archives of biochemistry and biophysics.

[7]  R. Cone,et al.  Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn. , 1999, Journal of medicinal chemistry.

[8]  V. Madison,et al.  Peptide mimetics of thyrotropin-releasing hormone based on a cyclohexane framework: design, synthesis, and cognition-enhancing properties. , 1995, Journal of medicinal chemistry.

[9]  M. Belfort,et al.  Mechanisms of Intron Mobility (*) , 1995, The Journal of Biological Chemistry.

[10]  C. Dooley,et al.  New opioid peptides, peptidomimetics, and heterocyclic compounds from combinatorial libraries. , 1999, Biopolymers.

[11]  S. Sprang,et al.  Structure of RGS4 Bound to AlF4 −-Activated Giα1: Stabilization of the Transition State for GTP Hydrolysis , 1997, Cell.

[12]  K. Ward,et al.  Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. , 2000, Journal of medicinal chemistry.

[13]  D. Rhodes,et al.  Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. , 1991, Journal of medicinal chemistry.

[14]  J. García-Sancho,et al.  Cytochrome P450 may regulate plasma membrane Ca2+ permeability according to the filling state of the intracellular Ca2+ stores , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  E G McMahon,et al.  Conformational restriction of angiotensin II: cyclic analogues having high potency. , 1990, Journal of medicinal chemistry.

[16]  A G Cochran,et al.  Antagonists of protein-protein interactions. , 2000, Chemistry & biology.

[17]  B. Imperiali,et al.  Pyridoxamine-amino acid chimeras in semisynthetic aminotransferase mimics. , 1997, Protein engineering.

[18]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[19]  H. Khorana,et al.  Mapping light-dependent structural changes in the cytoplasmic loop connecting helices C and D in rhodopsin: a site-directed spin labeling study. , 1995, Biochemistry.

[20]  N. Gautam,et al.  A farnesylated domain in the G protein gamma subunit is a specific determinant of receptor coupling. , 1994, The Journal of biological chemistry.

[21]  M. Ghadiri,et al.  Secondary structure nucleation in peptides. Transition metal ion stabilized .alpha.-helices , 1990 .

[22]  M. Galas,et al.  Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds. , 1987, Journal of medicinal chemistry.

[23]  B H Arison,et al.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Schiller,et al.  The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. , 1999, Biopolymers.

[25]  A. Patchett,et al.  Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. , 1998, Journal of medicinal chemistry.

[26]  A T Brünger,et al.  Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody. , 1992, Science.

[27]  V J Hruby,et al.  Design of peptides, proteins, and peptidomimetics in chi space. , 1997, Biopolymers.

[28]  K Wüthrich,et al.  The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. , 1991, Biochemistry.

[29]  S. Karnik,et al.  The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*) , 1995, The Journal of Biological Chemistry.

[30]  P. Garratt,et al.  The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. , 1999, Bioorganic & medicinal chemistry letters.

[31]  J. Bali,et al.  Synthesis of pseudo-peptide analogues of the C-terminal tetrapeptide of gastrin and evaluation of their biological activity on acid secretion. , 2009, International journal of peptide and protein research.

[32]  Robyn L. Stanfield,et al.  An αβ T Cell Receptor Structure at 2.5 Å and Its Orientation in the TCR-MHC Complex , 1996, Science.

[33]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[34]  J. Becker,et al.  Synthesis, biological activity, and conformational analysis of peptidomimetic analogues of the Saccharomyces cerevisiae alpha-factor tridecapeptide. , 1998, Biochemistry.

[35]  S. Schreiber,et al.  Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. , 1995, Science.

[36]  Max F. Perutz,et al.  Hemoglobin as a receptor of drugs and peptides: x-ray studies of the stereochemistry of binding , 1986 .

[37]  T. Burks,et al.  Morphiceptin and β‐casomorphin‐5 analogues containing a reduced peptide bond: Selective μ‐receptor agonists and a novel μ antagonist, H‐Tyr‐Proψ(CH2‐NH)Phe‐Pro‐Gly‐OH , 1992 .

[38]  G. Wider,et al.  Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy , 1991, Nature.

[39]  I. Wilson,et al.  Structural evidence for induced fit as a mechanism for antibody-antigen recognition. , 1994, Science.

[40]  T. Schwartz,et al.  Metal‐Ion Sites as Structural and Functional Probes of Helix–Helix Interactions in 7TM Receptors , 1997, Annals of the New York Academy of Sciences.

[41]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Gallant,et al.  Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. , 2000, Chemistry & biology.

[43]  Klaus Hofmann,et al.  S-peptide-S-protein system. Model for hormone-receptor interaction , 1973 .

[44]  Paul A. Bartlett,et al.  Metal Coordination as a Method for Templating Peptide Conformation , 1996 .

[45]  Thyrotropin releasing hormone analogs: a building block approach to the construction of tetracyclic peptidomimetics. , 1998, Bioorganic & medicinal chemistry letters.

[46]  A. Smolyar,et al.  The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.

[47]  Berthold Von Freyberg,et al.  Receptor-induced conformation change of the immunosuppressant cyclosporin A. , 1991, Science.

[48]  V. Hruby,et al.  beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. , 1997, Journal of medicinal chemistry.

[49]  J Engel,et al.  Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. , 1994, The Journal of biological chemistry.

[50]  L. Suva,et al.  Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.

[51]  B. Meyer,et al.  Mapping the active site of angiotensin-converting enzyme by transferred NOE spectroscopy. , 2000, Journal of medicinal chemistry.

[52]  Henry I. Mosberg Complementarity of δ opioid ligand pharmacophore and receptor models , 1999 .

[53]  J. Bali,et al.  Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: the importance of the peptide backbone. , 1985, Journal of medicinal chemistry.

[54]  Y. Shi,et al.  Metallopeptide approach to the design of biologically active ligands: design of specific human neutrophil elastase inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[55]  J. Bushweller,et al.  Investigation of an octapeptide inhibitor of Escherichia coli ribonucleotide reductase by transferred nuclear Overhauser effect spectroscopy. , 1991, Biochemistry.

[56]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[57]  A. Gronenborn,et al.  Solution structure of a calmodulin-target peptide complex by multidimensional NMR. , 1994, Science.

[58]  W. Hutton,et al.  Emerimicins III and IV and Their Ethylalanine12 Epimers. Facilitated Chemical-Enzymatic Synthesis and a Qualitative Evaluation of Their Solution Structures , 1992 .

[59]  N. Tarasova,et al.  Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions* , 1999, The Journal of Biological Chemistry.

[60]  Garland R. Marshall,et al.  Pro-D-NMe-Amino Acid and D-Pro-NMe-Amino Acid: Simple, Efficient Reverse-Turn Constraints , 1995 .

[61]  B. Stoddard,et al.  Calcineurin-immunosuppressor complexes. , 1996, Current opinion in structural biology.

[62]  A Aubry,et al.  A crystal molecular conformation of leucine‐enkephalin related to the morphine molecule , 1989, Biopolymers.

[63]  The structure of aridicin A. An integrated approach employing 2D NMR, energy minimization and distance constraints , 1986 .

[64]  M. Katharine Holloway,et al.  X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .

[65]  D. Coy,et al.  Effect of the CH2NH and CH2NAc peptide bond isosteres on the antagonistic and histamine releasing activities of a luteinizing hormone-releasing hormone analogue. , 1988, Journal of medicinal chemistry.

[66]  Anna Tempczyk,et al.  Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.

[67]  J. Becker,et al.  Mutations affecting ligand specificity of the G-protein-coupled receptor for the Saccharomyces cerevisiae tridecapeptide pheromone. , 1998, Biochimica et biophysica acta.

[68]  J. Louis,et al.  Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.

[69]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[70]  K. Nakanishi,et al.  Movement of retinal along the visual transduction path. , 2000, Science.

[71]  C. W. Roberts,et al.  THE SYNTHESIS OF AN OCTAPEPTIDE AMIDE WITH THE HORMONAL ACTIVITY OF OXYTOCIN , 1953 .

[72]  Dorica Mayer,et al.  A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies , 1987, J. Comput. Aided Mol. Des..

[73]  D. Rich,et al.  Peptidomimetics derived from natural products , 1993, Medicinal research reviews.

[74]  Stephen W. Fesik,et al.  Lithium chloride perturbation of cis-trans peptide bond equilibria: effect on conformational equilibria in cyclosporin A and on time-dependent inhibition of cyclophilin , 1992 .

[75]  K Wüthrich,et al.  TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Tyrosine alone exhibits opiate-like activity when linked to an amphipathic hydrocarbon chain , 1988 .

[77]  A. Tomasselli,et al.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.

[78]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[80]  K. Hofmann,et al.  Signal transfer from rhodopsin to the G-protein: evidence for a two-site sequential fit mechanism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[81]  X Zhang,et al.  A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.

[82]  Maria Miller,et al.  Crystal structure of a retroviral protease proves relationship to aspartic protease family , 1989, Nature.

[83]  D. Underwood,et al.  Structural Requirements for the Activation of the Human Growth Hormone Secretagogue Receptor by Peptide and Nonpeptide Secretagogues , 1997 .

[84]  P. Hopkins,et al.  Metal ion enhanced helicity in synthetic peptides containing unnatural, metal-ligating residues , 1990 .

[85]  I. Mian,et al.  Structure, function and properties of antibody binding sites. , 1991, Journal of molecular biology.

[86]  K. Garcia,et al.  Structural basis of T cell recognition. , 1999, Annual review of immunology.

[87]  D. Coy,et al.  Solid-phase synthesis and biological properties of psi [CH2NH] pseudopeptide analogues of a highly potent somatostatin octapeptide. , 1987, Journal of medicinal chemistry.

[88]  W. Vale,et al.  D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. , 1975, Biochemical and biophysical research communications.

[89]  D Altschuh,et al.  A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. , 1992, Science.

[90]  P E Wright,et al.  Defining solution conformations of small linear peptides. , 1991, Annual review of biophysics and biophysical chemistry.

[91]  G. Bitan,et al.  Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.

[92]  G R Marshall,et al.  Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation. , 1995, Journal of medicinal chemistry.

[93]  A. Doig,et al.  Toward the semiquantitative estimation of binding constants guides for peptide peptide binding in aqueous solution , 1991 .

[94]  H. Hamm,et al.  The 2.0 Å crystal structure of a heterotrimeric G protein , 1996, Nature.

[95]  I. Gantz,et al.  Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.

[96]  S. O. Smith,et al.  Magic angle spinning NMR of the protonated retinylidene Schiff base nitrogen in rhodopsin: expression of 15N-lysine- and 13C-glycine-labeled opsin in a stable cell line. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Garland R. Marshall,et al.  Three-dimensional structure of peptide—protein complexes: implications for recognition , 1992 .

[98]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[99]  D. Coy,et al.  Analogues of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region. , 1990, Journal of medicinal chemistry.

[100]  H. Khorana,et al.  Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. , 1996, Biochemistry.

[101]  Garland R. Marshall,et al.  3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries , 1993 .

[102]  K. Aston,et al.  Synthesis of conformationally tailored pentaazacyclopentadecanes. Preorganizing peptide cyclizations , 1997 .

[103]  L. Suva,et al.  Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Stephen Hanessian,et al.  Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics , 1997 .

[105]  C. Dobson,et al.  Antigen mobility in the combining site of an anti-peptide antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Luis Reuss Focus on "Effect of expressing the water channel aquaporin-1 on the CO2 permeability of Xenopus oocytes". , 1998, American journal of physiology. Cell physiology.

[107]  G. Marshall,et al.  Determination of a precise interatomic distance in a helical peptide by REDOR NMR , 1990 .

[108]  E. R. Stimson,et al.  Mapping Peptide-binding Domains of the Substance P (NK-1) Receptor from P388D Cells with Photolabile Agonists (*) , 1995, The Journal of Biological Chemistry.

[109]  R. Hirschmann Medicinal Chemistry in the Golden Age of Biology: Lessons from Steroid and Peptide Research , 1991 .

[110]  J. Rothbard,et al.  Interactions between Immunogenic Peptides and MHC Proteins , 1991 .

[111]  G. Byk,et al.  Comparison of the conformation of active and nonactive backbone cyclic analogs of substance P as a tool to elucidate features of the bioactive conformation: NMR and molecular dynamics in DMSO and water. , 1994, Journal of medicinal chemistry.

[112]  D. Riley,et al.  Manganese macrocyclic ligand complexes as mimics of superoxide dismutase , 1994 .

[113]  D. Madden The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[114]  Shu-Kun Lin Pharmacophore Perception, Development and Use in Drug Design. Edited by Osman F. Güner , 2000 .

[115]  G. Marshall,et al.  Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. , 1996, Journal of medicinal chemistry.

[116]  R. Huber,et al.  The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. , 1994, The Journal of biological chemistry.

[117]  S. Karnik,et al.  Interaction of Phe8 of Angiotensin II with Lys199 and His256 of AT1 Receptor in Agonist Activation (*) , 1995, The Journal of Biological Chemistry.

[118]  G R Marshall,et al.  Factors governing helical preference of peptides containing multiple alpha,alpha-dialkyl amino acids. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[119]  H. Hamm,et al.  Potent Peptide Analogues of a G Protein Receptor-binding Region Obtained with a Combinatorial Library (*) , 1996, The Journal of Biological Chemistry.

[120]  J. Bali,et al.  Phenylethylamide derivatives of the C-terminal tetrapeptide of gastrin. Potent inhibitors of gastrin-stimulated acid secretion. , 2009, International journal of peptide and protein research.

[121]  J. Alderfer,et al.  Three-dimensional structure of the cytoplasmic face of the G protein receptor rhodopsin. , 1997, Biochemistry.

[122]  G R Marshall,et al.  Light-activated rhodopsin induces structural binding motif in G protein alpha subunit. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[123]  W. Greenlee,et al.  Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. , 1997, Molecular pharmacology.

[124]  H. Scheraga,et al.  High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen. , 1989, Biochemistry.

[125]  P. Caron,et al.  X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex , 1995, Cell.

[126]  A. Milon,et al.  Transferred nuclear Overhauser effect analyses of membrane-bound enkephalin analogues by 1H nuclear magnetic resonance: correlation between activities and membrane-bound conformations. , 1990, Biochemistry.

[127]  J. Springer,et al.  Structure and function of retroviral proteases. , 1991, Annual review of biophysics and biophysical chemistry.

[128]  G R Marshall,et al.  Conformationally restricted TRH analogs: a probe for the pyroglutamate region. , 1996, Journal of medicinal chemistry.

[129]  N. Gautam,et al.  Efficient Interaction with a Receptor Requires a Specific Type of Prenyl Group on the G Protein γ Subunit (*) , 1995, The Journal of Biological Chemistry.

[130]  Garland R. Marshall,et al.  Electrochemical Cyclization of Dipeptides toward Novel Bicyclic, Reverse-Turn Peptidomimetics. 1. Synthesis and Conformational Analysis of 7,5-Bicyclic Systems , 1995 .

[131]  V. Chhajlani,et al.  Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. , 1996, Biochemical and biophysical research communications.

[132]  G. Turcatti,et al.  Characterization of Non-peptide Antagonist and Peptide Agonist Binding Sites of the NK1 Receptor with Fluorescent Ligands* , 1997, The Journal of Biological Chemistry.

[133]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[134]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[135]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[136]  P. Schiller,et al.  Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. , 1998, Journal of medicinal chemistry.

[137]  K. Garcia,et al.  Recognition of angiotensin II: antibodies at different levels of an idiotypic network are superimposable. , 1992, Science.

[138]  O. Lichtarge,et al.  Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F , 1996, Nature.

[139]  M. Schreier,et al.  Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity , 1987, European journal of immunology.

[140]  J M Sturtevant,et al.  Heat capacity changes for protein-peptide interactions in the ribonuclease S system. , 1992, Biochemistry.

[141]  Amos B. Smith,et al.  Novel ligands lacking a positive charge for the δ- and μ-opioid receptors , 2000 .

[142]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[143]  D. Seebach,et al.  Novel backbone conformation of cyclosporin A: the complex with lithium chloride , 1992 .

[144]  Y. Shigeri,et al.  A potent nonpeptide neuropeptide Y Y1 receptor antagonist, a benzodiazepine derivative. , 1998, Life sciences.

[145]  C. Martínez-A,et al.  HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[146]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[147]  A. Otaka,et al.  An anti-HIV peptide, T22, forms a highly active complex with Zn(II). , 1996, Biochemical and biophysical research communications.

[148]  D. Fairlie,et al.  Conformational homogeneity in molecular recognition by proteolytic enzymes , 1999, Journal of molecular recognition : JMR.

[149]  F A Quiocho,et al.  Target enzyme recognition by calmodulin: 2.4 A structure of a calmodulin-peptide complex. , 1992, Science.

[150]  E Novellino,et al.  Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. , 2000, Journal of medicinal chemistry.

[151]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[152]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[153]  J. Chang Deciphering the structural elements of hirudin C-terminal peptide that bind to the fibrinogen recognition site of alpha-thrombin. , 1991, Biochemistry.

[154]  K. Wüthrich,et al.  Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance. , 1989, Biochemistry.

[155]  W. Greenlee,et al.  Non-peptide Angiotensin Agonist , 1995, The Journal of Biological Chemistry.

[156]  Stephen W. Fesik,et al.  A model of the cyclophilin/cyclosporin A (CSA) complex from NMR and X-ray data suggests that CSA binds as a transition-state analog , 1992 .

[157]  A. Otaka,et al.  Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.

[158]  S. Goodman,et al.  Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists , 1996 .

[159]  X. P. Liu,et al.  The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. , 1996, Biochemistry.

[160]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[161]  S. Jurisson,et al.  Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[162]  G. Rose,et al.  Turns in peptides and proteins. , 1985, Advances in protein chemistry.

[163]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[164]  R. Leduc,et al.  Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure. , 2000, Biochemistry.

[165]  E. Purisima,et al.  Conformational stability of a thrombin-binding peptide derived from the hirudin C-terminus. , 1992, Biochemistry.

[166]  Garland R. Marshall,et al.  Conformational Analysis of Reverse-Turn Constraints by N-Methylation and N-Hydroxylation of Amide Bonds in Peptides and Non-Peptide Mimetics , 1998 .

[167]  S W Lin,et al.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[168]  R G Smith,et al.  Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.

[169]  M. Ghadiri,et al.  Peptide architecture. Design of stable .alpha.-helical metallopeptides via a novel exchange-inert ruthenium(III) complex , 1990 .

[170]  G. Wider,et al.  Cyclosporin A—cyclophilin complex formation A model based on X‐ray and NMR data , 1992, FEBS letters.

[171]  A. Lomize,et al.  The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. , 1997, Biophysical journal.

[172]  R. Jensen,et al.  Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists. , 1991, The Journal of biological chemistry.

[173]  J. Rizo,et al.  Constrained peptides: models of bioactive peptides and protein substructures. , 1992, Annual review of biochemistry.

[174]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[175]  Garland R. Marshall,et al.  A hierarchical approach to peptidomimetic design , 1993 .

[176]  R. Leduc,et al.  Molecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding. , 2000, Biochimica et biophysica acta.

[177]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[178]  S. Mammi,et al.  Conformational studies by circular dichroism, 1H NMR, and computer simulations of bombolitins I and III in aqueous solution containing surfactant micelles. , 1990, Biochemistry.

[179]  R. Schwyzer Peptide–membrane interactions and a new principle in quantitative structure–activity relationships , 1991, Biopolymers.

[180]  D. Robertson,et al.  Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. , 2000, Journal of medicinal chemistry.

[181]  V. Hruby,et al.  Conformational and topographical considerations in the design of biologically active peptides , 1993, Biopolymers.

[182]  V. Hruby,et al.  Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. , 1999, Biopolymers.

[183]  W. Bode,et al.  Crystal structure of the thrombin‐hirudin complex: a novel mode of serine protease inhibition. , 1990, The EMBO journal.

[184]  William L. Neumann,et al.  Asymmetric synthesis of highly functionalized polyazamacrocycles via reduction of cyclic peptide precursors , 1994 .

[185]  Dudley H. Williams,et al.  Aspects of molecular recognition: solvent exclusion and dimerization of the antibiotic ristocetin when bound to a model bacterial cell-wall precursor , 1989 .

[186]  K. R. Ely,et al.  Synthetic site-directed ligands. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[187]  M. Saraste,et al.  FEBS Lett , 2000 .

[188]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[189]  N. Sewald,et al.  Peptides: Chemistry and Biology , 2002 .

[190]  J. Zheng,et al.  Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[191]  W. Vale,et al.  Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. , 1973, Biochemistry.

[192]  I. Hamachi,et al.  Guest-Induced Umpolung on a Protein Surface: A Strategy for Regulation of Enzymatic Activity , 2000 .

[193]  K. Blumer,et al.  G-protein-coupled receptors function as oligomers in vivo , 2000, Current Biology.

[194]  R. Poljak,et al.  Three-dimensional structure of an idiotope–anti-idiotope complex , 1990, Nature.

[195]  D. Patel,et al.  RNA architecture dictates the conformations of a bound peptide. , 1999, Chemistry & biology.

[196]  S. Rees,et al.  Chapter 24. Oligomerisation of G protein-coupled receptors , 2000 .

[197]  C. Strader,et al.  A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. , 1989, The Journal of biological chemistry.

[198]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[199]  R. Jensen,et al.  Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. , 1988, The Journal of biological chemistry.

[200]  M. Casu,et al.  Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors: synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor. , 1999, Biopolymers.

[201]  R. Dixon,et al.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.

[202]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[203]  B Kohl,et al.  From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. , 1997, Journal of medicinal chemistry.

[204]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[205]  J. Rivier,et al.  Betidamino acids: versatile and constrained scaffolds for drug discovery. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[206]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[207]  Garland R. Marshall,et al.  Constrained Peptidomimetics for TRH: cis-Peptide Bond Analogs , 2000 .